Immunologic Issues in Type 1 Diabetes

Immunologic issues in type 1 diabetes.

Jay Skyler, Miami, FL, presented the results of the parenteral substudy arm of the Diabetes Prevention Trial for Type 1 Diabetes (DPT-1), in which relatives of patients with type 1 diabetes, whose risk of type 1 diabetes is 10to 20-fold greater than that of the general population, were screened for islet cell antibodies (ICAs) and enrolled in a study of insulin administration if they showed hig...

Immunologic and genetic factors in type 1 diabetes.

Diabetes mellitus (DM) is a metabolic disorder resulting from a defect in insulin secretion, insulin action, or both (Kumar et al., 2002). In type 1 diabetes, the body does not produce insulin. Insulin is a hormone that is needed to convert sugar, starches and other food into energy needed for daily life. Insulin deficiency in turn leads to chronic hyperglycaemia with disturbances of carbohydra...

Immunologic and Genetic Factors in Type 1 Diabetes Mellitus

Treatment issues in type 1 diabetes.

Glucose monitoring and sensing In a symposium at the ADA meeting, Charles M. Peterson, Bethesda, MD, gave an overview of noninvasive glucose monitoring, stressing the need to critically evaluate the differing technologies. Since 1995 there have been 8 new drugs, 8 new insulins, and 35 new meters introduced on the market; glucose monitoring is a huge industry that is growing by 15% annually. Pet...

Clinical immunologic interventions for the treatment of type 1 diabetes.

Type 1 diabetes is an autoimmune disease, hence the rationale for immunotherapy to halt disease progression. Based on knowledge gained from other autoimmune diseases and from transplantation, the first immunointervention trials used immunosuppressive drugs, e.g., cyclosporin, in patients with recently diagnosed type 1 diabetes. Although remarkable, the effect vanished following drug withdrawal....